Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Recruiting now · Phase 3

Conditions studied: Hidradenitis Suppurativa (HS)

In brief

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Key facts

Study ID

NCT06855498

Run by

Incyte Corporation

People needed

600

Starts

2025-02-28

Expected to finish

2028-02-28

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to comprehend and willingness to sign a written ICF for the study.
• Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
• Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
• Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
• Willingness to avoid pregnancy or fathering children as defined in the protocol.
• Willingness and ability to comply with the study Protocol and procedures.

You may not qualify if…

• Had been permanently discontinued from study treatment during the parent study.
• Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
• Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
• Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
• Live, attenuated vaccine.
• Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
• Women who are pregnant (or who are considering pregnancy) or breastfeeding.
• Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.
• Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
• Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
• Other protocol-defined Inclusion/Exclusion Criteria may apply.

Where it is running

• Investigative Site US079 — Miami Lakes, Florida, United States (enrolling)
• Investigative Site US035 — Tampa, Florida, United States (enrolling)
• Investigative Site US062 — Miami, Florida, United States (enrolling)
• Investigative Site US072 — Miami Lakes, Florida, United States (enrolling)
• Investigative Site US029 — Ocala, Florida, United States (enrolling)
• Investigative Site US076 — Fountain Valley, California, United States (enrolling)
• Investigative Site US077 — Fremont, California, United States (enrolling)
• Investigative Site US004 — Phoenix, Arizona, United States (enrolling)
• Investigative Site US086 — Birmingham, Alabama, United States (enrolling)
• Investigative Site US015 — Miami, Florida, United States (enrolling)
• Investigative Site US036 — Los Angeles, California, United States (enrolling)
• Investigative Site US023 — North Miami Beach, Florida, United States (enrolling)
• Investigative Site US067 — Los Angeles, California, United States (enrolling)
• Investigative Site US060 — Northridge, California, United States (enrolling)
• Investigative Site US037 — Oakland, California, United States (enrolling)
• Investigative Site US089 — Santa Monica, California, United States (enrolling)
• Investigative Site US080 — Sherman Oaks, California, United States (enrolling)
• Investigative Site US071 — Huntington Beach, California, United States (enrolling)
• Investigative Site US097 — Irvine, California, United States (enrolling)
• Investigative Site US002 — Boca Raton, Florida, United States (enrolling)
• Investigative Site US020 — Laguna Niguel, California, United States (enrolling)
• Investigative Site US084 — Coral Gables, Florida, United States (enrolling)
• Investigative Site US017 — Hialeah, Florida, United States (enrolling)
• Investigative Site US019 — Hollywood, Florida, United States (enrolling)
• Investigative Site US005 — Tampa, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.